What are the Historical Developments and Current Growth Metrics of the Predictive Biomarkers Market?
The predictive biomarkers market has seen considerable growth due to a variety of factors.
• In the latest years, the predictive biomarkers marketplace has seen a steady expansion. The market, valued at $20.05 billion in 2024, is projected to reach a value of $20.96 billion in 2025, signalling a compound annual growth rate (CAGR) of 4.5%.
This progressive shift during the historical period is due to a rise in research and development funding, the expansion of healthcare infrastructure, cooperative endeavours between academic institutions and industry sectors, a higher occurrence of cancer and genetic anomalies, and the escalated usage of biomarkers in the field of drug discovery and development.
What Is The Projected Growth Of The Predictive Biomarkers Template Market?
The predictive biomarkers market is expected to maintain its strong growth trajectory in upcoming years.
• The market for predictive biomarkers is set for consistent expansion in the coming years, reaching a value of $24.67 billion in 2029, with an annual growth rate of 4.2%.
This growth during the forecast period can be credited to the increasing implementation of precision medicine, a heightened emphasis on preventive healthcare, growing healthcare expenses, escalating investment in biomarker-based diagnosis, growth of biobanks and tissue repositories, and an enhanced global health consciousness. The expected trends during this time frame will likely be the integration of artificial intelligence into biomarker analysis, progression in non-invasive biomarker testing, improvements in biomarker-driven digital health devices, advances in single-cell sequencing technologies, the inception of real-time biosensing and monitoring systems, and progress in bioinformatic tools for data integration.
What Are The Key Drivers Fueling Growth In The Predictive Biomarkers Market?
The predictive biomarkers market is anticipated to grow due to the increasing incidence of cancer, a condition characterized by uncontrolled cell growth that can spread and invade other regions of the body. The expanding number of cancer incidents can be ascribed to an aging population, lifestyle shifts, and enhanced exposure to risk aspects like tobacco, unhealthy eating habits, and environmental pollutants. Predictive biomarkers in cancer provide a means to determine which patients are most likely to benefit from specific treatments, facilitating more personalized and effective therapy. As per a report by the International Agency for Research on Cancer (IARC), a specialized cancer research branch of the World Health Organization (WHO) based in France, approximately 20 million new cancer cases and around 10 million cancer-related fatalities occurred in 2022. Furthermore, estimates propose that the yearly count of new cancer cases could surge to 35 million by 2050, indicating a 77% growth from the levels of 2022. Hence, the predictive biomarkers market will expand due to the increasing cases of cancer.
What Are The Principal Market Segments In The Global Predictive Biomarkers Industry?
The predictive biomarkers market covered in this report is segmented –
1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications
2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring
3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users
Subsegments:
1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer
2) By Metabolic Disease: Type 1 and Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance
3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease
4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Immunodeficiency Disorders
5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders
Pre-Book The Predictive Biomarkers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Predictive Biomarkers Market?
Leading enterprises in the predictive biomarkers market are prioritizing the acceleration of biomarker development via technological breakthroughs. They leverage artificial intelligence (AI) to facilitate biomarker discovery, aiming at attaining a competitive advantage by providing more customized and efficient treatments promptly. AI-facilitated biomarker discovery encourages the analysis of substantial, multifaceted datasets, which helps in identifying predictive biomarkers that may not be visible through conventional techniques. For instance, Scipher Medicine, Inc., an American precision immunology firm, set afoot their PRoBeNet (Predictive Response Biomarkers using Network Medicine) in July 2024. This initiative is directed towards accelerating the evolution of predictive response biomarkers for complicated diseases by integrating AI and network biology. PRoBeNet recognizes biomarkers of therapeutic response by merging therapy-targeted proteins and disease-specific molecular signatures. It has been authenticated for autoimmune illnesses such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease, and can also be utilized for other intricate diseases and pharmaceutical development phases.
Who Are the Key Players In The Predictive Biomarkers Market?
Major companies operating in the predictive biomarkers market are:
• Johnson & Johnson Services Inc
• F Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc
• Abbott Laboratories
• Danaher Corporation
• Merck KGaA
• Siemens Healthcare GmbH
• Agilent Technologies Inc
• PerkinElmer Inc
• Illumina Inc
• Bio-Rad Laboratories Inc
• QIAGEN GmbH
• Almac Group Limited
• ArcherDX Inc
• Luminex Corporation
• Guardant Health Inc
• Meso Scale Diagnostics LLC
• Myriad Genetics Inc
• NanoString Technologies Inc
• Fujirebio Inc
• Asuragen Inc
• Biognosys AG
• Epigenomics AG
• OncoCyte Corporation
• Biomarker Technologies Inc
What Are The Regional Insights Into The Predictive Biomarkers Market?
North America was the largest region in the predictive biomarkers market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
